Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-12T21:27:29.532Z Has data issue: false hasContentIssue false
  • English
  • Français

Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: An open trial

Published online by Cambridge University Press:  15 April 2020

G. Scantamburlo ,
M. Hansenne ,
V. Geenen ,
J.J. Legros  and
M. Ansseau
G. Scantamburlo*
Affiliation:
Department of Psychiatry, Psychoneuroendocrinology Unit, University of Liège, Liège, Belgium
M. Hansenne
Affiliation:
Department of Cognitive Sciences, Faculty of Psychology, University of Liège, Liège, Belgium
V. Geenen
Affiliation:
Immunoendocrinology Center, GIGA3, University of Liège, Liège, Belgium
J.J. Legros
Affiliation:
Departement of Endocrinology, Psychoneuroendocrinology Unit, University of Liège, Liège, Belgium
M. Ansseau
Affiliation:
Department of Psychiatry, Psychoneuroendocrinology Unit, University of Liège, Liège, Belgium
*
*Corresponding author. Tel.: +32 4 366 79 60. E-mail address:Gabrielle.Scantamburlo@ulg.ac.be (G. Scantamburlo).
Get access

Abstract

The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as an adjunct to antidepressant in treatment-resistant depression. Fourteen patients, who have not responded to 40 mg of escitalopram, received intranasal synthetic oxytocin during 4 weeks, in association with antidepressant. This is the first open trial study suggesting OT in association with escitalopram significantly reduced scores on Hamilton Depression Rating Scale.

Keywords

Major depressionIntranasal oxytocinAnxiety
Type
Short communication
Information
European Psychiatry , Volume 30 , Issue 1 , January 2015 , pp. 65 - 68
Copyright
Copyright © Elsevier Masson SAS 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cardoso, C, Ellenbogen, M, Linnen, A. Acute intranasal oxytocin improves positive self-perceptions of personality. Psychopharmacology 2012;220:741–749.CrossRefGoogle ScholarPubMed
Domes, G, Lischke, A, Berger, C, Grossmann, A, Hauenstein, K, Heinrichs, M, et al.Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2010;35:83–93.CrossRefGoogle ScholarPubMed
Ellenbogen, MA, Linnen, AM, Cardoso, C, Joober, R. Intranasal oxytocin impedes the ability to ignore task-irrelevant facial expressions of sadness in students with depressive symptoms. Psychoneuroendocrinology 2013;38:387–398.CrossRefGoogle ScholarPubMed
Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29:321–326.Google ScholarPubMed
Emiliano, A, Cruz, T, Pannoni, V, et al.The interface of oxytocin-labeled cells and serotonin. Neuropsychopharmacology 2006;11:1–12.Google Scholar
Forkmann, T, Scherer, A, Boecker, M, et al.The clinical global Impression scale and the influence of patient or staff perspective on outcome. BMC Psychiatry 2011;11(1):83.CrossRefGoogle ScholarPubMed
Furman, DJ, Chen, MC, Gotlib, IH. Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology 2011;36:891–897.CrossRefGoogle ScholarPubMed
Heinrichs, M, Baumgartner, T, Kirschbaum, C, Ehlert, U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003;54:1389–1398.CrossRefGoogle ScholarPubMed
Keating, C, Dawood, T, Barton, D, Lambert, G, Tilbrook, A. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder. BMC Psychiatry 2013;29(13):124.CrossRefGoogle Scholar
Lischke, A, Gamer, M, Berger, C, Grossmann, A, Hauenstein, K, Heinrichs, M, et al.Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology 2012;37:1431–1438.CrossRefGoogle ScholarPubMed
Macdonald, K, Feifel, D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci 2013;7:1–21.CrossRefGoogle ScholarPubMed
Mah, BL, Van Ijzendoorn, MH, Smith, R, Bakermans-Kranenburg, MJ. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog in Neuropsychopharmacol Biol Psychiatr 2013;40:267–272.CrossRefGoogle ScholarPubMed
Matsuki, M, Matsushita, H, Tomizawa, K, Matsui, H. Oxytocin: a therapeutic target for mental disorder. J Physiol Sci 2012;62:441–444.CrossRefGoogle Scholar
Mendlewicz, J, Crisafulli, C, Calati, R, Kocabas, NA, Massat, I, Linotte, S, et al.Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. Neurosci Lett 2012;10(516):85–88.CrossRefGoogle Scholar
Meyer-Lindenberg, A, Domes, G, Kirsch, P, Heinrichs, M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 2011;19(12):524–538.CrossRefGoogle Scholar
Miller, G. The promise and perils of oxytocin. Science 2013;339:267–269.CrossRefGoogle ScholarPubMed
Legros, JJ. Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying–yang neurohormones?. Psychoneuroendocrinology 2011;26:649–655.CrossRefGoogle Scholar
Okimoto, N, Bosch, OJ, Slattery, DA, Pflaum, K, Matsushita, H, Wei, FY, et al.RGS2 mediates the anxiolytic effect of oxytocin. Brain Res 2012;9(1453):26–33.CrossRefGoogle Scholar
Ozsoy, S, Esel, E, Kula, M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009;30(169):249–252.CrossRefGoogle Scholar
Parker, KJ, Kenna, HA, Zeitzer, JM, Keller, J, Blasey, CM, Amico, JA, et al.Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res 2010;178:359–362.CrossRefGoogle ScholarPubMed
Pincus, D, Kose, S, Arana, A, Johnson, K, Morgan, P, Borckardt, J, et al.Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled fMRI study. Front Psychiatr 2010;1.Google ScholarPubMed
Scantamburlo, G, Hansenne, M, Fuchs, S, Pitchot, W, Maréchal, P, Pequeux, C, et al.Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007;32:407–410.CrossRefGoogle ScholarPubMed
Scantamburlo, G, Ansseau, M, Geenen, V, Legros, JJ. Intranasal oxytocin as an adjunct to escitalopram in major depression. J Neuropsychiatry Clin Neurosci 2011;23:2.CrossRefGoogle ScholarPubMed
Spielberger, CD, Gorsuch, RL, Lushene, R, Vagg, PR, Jacobs, GAManual for the state-trait anxiety inventory. Consulting psychologists’ press CA: Palo Alto; 1983.Google Scholar
Turan, T, Uysal, C, Asdemir, A, Kilic, EMay oxytocin be a trait marker for bipolar disorder?. Psychoneuroendocrinology 2013;38:2890–2896.CrossRefGoogle ScholarPubMed
Uvnäs-Moberg, KAntistress pattern induced by oxytocin. News Physiol Sci 1998;13:22–25.Google ScholarPubMed
van Ijzendoorn, M, Bhandari, R, van der Veen, R, Grewen, K, Bakermans-Kranenburg, MJElevated salivary levels of oxytocin persist more than seven hours after intranasal administration. Front Neurosci 2012;6:174.CrossRefGoogle Scholar
Zink, C, Meyer-Lindenberg, AHuman neuroimaging of ocytocin and vasopressin in social cognition. Horm Behav 2012;61:400–409.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.